MA39942A - Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2 - Google Patents
Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2Info
- Publication number
- MA39942A MA39942A MA039942A MA39942A MA39942A MA 39942 A MA39942 A MA 39942A MA 039942 A MA039942 A MA 039942A MA 39942 A MA39942 A MA 39942A MA 39942 A MA39942 A MA 39942A
- Authority
- MA
- Morocco
- Prior art keywords
- radiotherapy
- treatment
- positive cancers
- combination
- immuno therapy
- Prior art date
Links
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000011220 combination immunotherapy Methods 0.000 title 1
- 238000011258 immunoradiotherapy Methods 0.000 title 1
- 241000282465 Canis Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des méthodes servant à induire une réponse immunitaire contre une tumeur exprimant l'antigène her-2/neu et à traiter celle-ci et à vacciner contre celle-ci des patients humains et canins par le biais de la combinaison de la radiothérapie et d'un vaccin de souche
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/268,436 US20140234370A1 (en) | 2009-11-11 | 2014-05-02 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
US201462076411P | 2014-11-06 | 2014-11-06 | |
PCT/US2015/017559 WO2015130810A2 (fr) | 2014-02-25 | 2015-02-25 | Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu |
US14/669,629 US10016617B2 (en) | 2009-11-11 | 2015-03-26 | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39942A true MA39942A (fr) | 2017-03-08 |
Family
ID=54359144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039942A MA39942A (fr) | 2014-05-02 | 2015-04-02 | Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3137107A4 (fr) |
JP (1) | JP2017514904A (fr) |
KR (1) | KR20170002552A (fr) |
CN (1) | CN106794234A (fr) |
AU (1) | AU2015253737A1 (fr) |
CA (1) | CA2947677A1 (fr) |
IL (1) | IL248704A0 (fr) |
MA (1) | MA39942A (fr) |
MX (1) | MX2016014367A (fr) |
SG (1) | SG11201609135VA (fr) |
WO (1) | WO2015167748A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
EP2683400A4 (fr) | 2011-03-11 | 2014-09-17 | Advaxis | Adjuvants à base de listeria |
SG11201405605VA (en) | 2012-03-12 | 2014-10-30 | Advaxis Inc | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT |
WO2015126921A1 (fr) | 2014-02-18 | 2015-08-27 | Advaxis, Inc. | Immunothérapie multi-cibles dirigée contre un biomarqueur |
WO2015164121A1 (fr) | 2014-04-24 | 2015-10-29 | Advaxis, Inc. | Souches de listeria utilisées comme vaccin recombinant et procédé de production |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
JP2019521099A (ja) * | 2016-06-03 | 2019-07-25 | エトゥビクス コーポレーション | Her2/neuを含む、腫瘍ワクチン接種及び免疫療法のための組成物及び方法 |
SG10202105561PA (en) | 2016-11-30 | 2021-07-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
MX2020003100A (es) | 2017-09-19 | 2020-08-20 | Advaxis Inc | Composiciones y metodos para la liofilizacion de bacterias o cepas de listeria. |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
US7432304B2 (en) * | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
US20050281783A1 (en) * | 2003-10-15 | 2005-12-22 | Kinch Michael S | Listeria-based EphA2 vaccines |
US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US9084747B2 (en) * | 2009-11-11 | 2015-07-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors |
WO2011100754A1 (fr) * | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Vaccins à base d'une listeria vivante à titre de thérapie pour le système nerveux central |
EP2576791B8 (fr) * | 2010-05-23 | 2016-12-21 | Aduro BioTech, Inc. | Procédés et compositions utilisant la listeria pour un traitement du cancer par adjuvant |
-
2015
- 2015-04-02 CN CN201580036168.0A patent/CN106794234A/zh active Pending
- 2015-04-02 SG SG11201609135VA patent/SG11201609135VA/en unknown
- 2015-04-02 WO PCT/US2015/024048 patent/WO2015167748A1/fr active Application Filing
- 2015-04-02 CA CA2947677A patent/CA2947677A1/fr not_active Abandoned
- 2015-04-02 JP JP2017509588A patent/JP2017514904A/ja not_active Ceased
- 2015-04-02 AU AU2015253737A patent/AU2015253737A1/en not_active Abandoned
- 2015-04-02 EP EP15786740.9A patent/EP3137107A4/fr not_active Withdrawn
- 2015-04-02 MX MX2016014367A patent/MX2016014367A/es unknown
- 2015-04-02 KR KR1020167033949A patent/KR20170002552A/ko unknown
- 2015-04-02 MA MA039942A patent/MA39942A/fr unknown
-
2016
- 2016-11-02 IL IL248704A patent/IL248704A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN106794234A (zh) | 2017-05-31 |
SG11201609135VA (en) | 2016-11-29 |
AU2015253737A1 (en) | 2016-12-22 |
CA2947677A1 (fr) | 2015-11-05 |
EP3137107A4 (fr) | 2018-01-17 |
EP3137107A1 (fr) | 2017-03-08 |
KR20170002552A (ko) | 2017-01-06 |
WO2015167748A1 (fr) | 2015-11-05 |
IL248704A0 (en) | 2017-01-31 |
MX2016014367A (es) | 2017-06-30 |
JP2017514904A (ja) | 2017-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39942A (fr) | Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2 | |
IL280707A (en) | Diagnostic and therapeutic methods for treating breast cancer | |
IL261008B1 (en) | Combined immunotherapy and cytokine control therapy for cancer treatment | |
IL297418B1 (en) | Combined immunotherapy and cytokine control therapy for cancer treatment | |
BR112018013731A2 (pt) | combinações anti-egfr para o tratamento de tumores | |
MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
IL272740A (en) | Combined immunotherapy and cytokine control therapy for cancer treatment | |
MX2019011148A (es) | Metodos de tratamiento. | |
BR112018013733A2 (pt) | combinações anti-cd20 para o tratamento de tumores a | |
MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
MX2016011114A (es) | Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu. | |
GEP20217317B (en) | Combination therapy for the treatment of cancer | |
FI3773689T3 (fi) | Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon | |
MX2019003722A (es) | Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. | |
MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
IL279591A (en) | Cancer treatment methods using combination therapy | |
IL281845A (en) | Combined treatment for cancer | |
IL281439A (en) | Combined treatment for blood cancer | |
IL284162A (en) | Integrated healing for cancer treatment | |
IL279277A (en) | In vivo controlled combination therapy for treatment of cancer | |
IL276068A (en) | iort device for radiotherapy treatment in cancer patients | |
EP4037761C0 (fr) | Dispositif pour le traitement par radiothérapie de patients atteints d'un cancer | |
IL275913A (en) | Methods and combined treatment for cancer treatment | |
MX2021001288A (es) | Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer. | |
IL271309A (en) | Methods for treating brain tumors through combined therapy |